UNSPSC 51242100: Combination nasal and throat preparations

This classification denotes combination drugs and preparations that a) treat infections of the upper respiratory tract organ responsible for sense of smell, or the nose and nasal passages therein; and/or b) infections of the funnel-shaped fibromuscular tube that conducts food to the ESOPHAGUS, and air to the LARYNX and LUNGS, known as the throat. These drugs, for these aforesaid reasons, bear the name NASAL AND THROAT PREPARATIONS. Typical combination nasal and throat preparation constituents are anethole, eucalyptus oil, glycerin, menthol, naphazoline, pheniramine, and phenylephrine.

UNSPSC 51242100 Combination nasal and throat preparations is a Class code encompassing generic multi-source pharmaceuticals and over-the-counter products that state and local government facilities source through cooperative purchasing vehicles and direct manufacturer contracts. State and local buyers acquire these preparations — typically delivered through authorized pharmaceutical wholesalers — to stock in health clinics, emergency departments, correctional facilities, and other public-sector healthcare settings. The issuing bodies include state departments of administration, state procurement offices, and multistate cooperative purchasing alliances that aggregate demand across member states and subordinate municipalities. Vendors must maintain current Good Manufacturing Practices (cGMP) certification, comply with the Drug Supply Chain Security Act (DSCSA), hold contractual relationships with designated wholesalers equipped with chargeback systems, and meet comprehensive insurance requirements including $5,000,000 in commercial general liability coverage.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with availability across Minnesota, Oregon, and other participating member states. The solicitation requires vendors to supply products identified by National Drug Codes through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — with all products available in the marketplace by May 15, 2026 and contract effectiveness set for July 1, 2026. Evaluation emphasizes price competitiveness (75 percent weight), with additional scoring on fixed pricing for the contract term (10 percent), EDI capability (5 percent), compliance with administrative fee data format requirements (5 percent), and agreement to a 3 percent administrative fee (5 percent). The contract term spans two years for new responders with optional extensions, while incumbent vendor amendments align with existing agreement expiration dates through June 30, 2028.